Early Warning System

EIB-20200488

COVID-19 IMMUNOLOGIC PLANT-BASED MANUFACTURING

Early Warning System

COVID-19 IMMUNOLOGIC PLANT-BASED MANUFACTURING

EIB-20200488

Quick Facts

Countries	Mauritius
Financial Institutions	European Investment Bank (EIB)
Status	Approved
Bank Risk Rating	U
Voting Date	2020-12-16
Borrower	CAPE BIO PHARMS (PTY) LTD
Sectors	Education and Health, Industry and Trade
Investment Type(s)	Loan
Investment Amount (USD)	$ 46.35 million
Project Cost (USD)	$ 58.54 million

Project Description

According to bank provided information, the project aims to establish a new plant-based current Good Manufacturing Practice (cGMP)-level manufacturing facility together with related processing laboratories and climate-controlled hydroponic grow rooms to produce reagents for the testing and treatment of COVID-19 and other endemic African diseases (e.g. Ebola, dengue, measles, HIV or yellow fever) in Mauritius. The facility is expected to reach a production capacity equivalent to 100 million test kits and/or vaccines per month.

This innovative project intends to support substantial research and product development into areas of high, unmet medical needs by providing reagents to a plethora of diagnostic companies in the field of infectious diseases. The operation supports the control of the spread of COVID-19 as it will increase the supply of COVID-19 specific antigens and antibodies for rapid diagnostic test kits to detect whether the individual is infected with COVID-19, as well as if the individual was infected with the virus, providing critical data to determine how COVID-19 is spreading amongst communities.

Investment Description

- European Investment Bank (EIB)

Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	Cape Bio Pharms (PTY) Limited	Client	-

Contact Information

Contact information not provided at the time of disclosure

ACCESS TO INFORMATION

You can submit an information request for project information at: https://www.eib.org/en/infocentre/registers/request-form/request-form-default.htm

ACCOUNTABILITY MECHANISM OF EIB

The EIB Complaints Mechanism is designed to facilitate and handle complaints against the EIB by individuals, organizations or corporations affected by EIB activities. When exercising the right to lodge a complaint against the EIB, any member of the public has access to a two-tier procedure, one internal - the Complaints Mechanism Office - and one external - the European Ombudsman. A complaint can be lodged via a written communication addressed to the Secretary General of the EIB, via email to the dedicated email address: complaints@eib.org, by completing the online complaint form available at the following address: http://www.eib.org/complaints/form via fax or delivered directly to the EIB Complaints Mechanism Division, any EIB local representation office or any EIB staff. For further details, check: http://www.eib.org/attachments/strategies/complaints_mechanism_policy_en.pdf

When dissatisfied with a complaint to the EIB Complaints Mechanism, citizens can then turn towards the European Ombudsman. A memorandum of Understanding has been signed between the EIB and the European Ombudsman establishes that citizens (even outside of the EU if the Ombudsman finds their complaint justified) can turn towards the Ombudsman on issues related to 'maladministration' by the EIB. Note that before going to the Ombudsman, an attempt must be made to resolve the case by contacting the EIB. In addition, the complaint must be made within two years of the date when the facts on which your complaint is based became known to you. You can write to the Ombudsman in any of the languages of the European Union. Additional details, including filing requirements and complaint forms, are available at: http://www.ombudsman.europa.eu/atyourservice/interactiveguide.faces